The newly identified axis, linking EGFR activation to Sp1 expression via miR‐9 and KLF5, represents a robust biomarker of CTX activity and can explain why only a subset of HNSCC patients benefits from the combined use of RT+CTX. Here, EGFR is linked to head and neck squamous cell carcinoma.